Nitric oxide dysfunction in vascular endothelium and platelets: Role in essential hypertension

Journal of Hypertension

Volumn 27, Issue 12, 2009, Pages 2310-2320

  Gkaliagkousi, Eugenia ^a,b   Douma, Stella ^b   Zamboulis, Chrysanthos ^b   Ferro, Albert ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Endothelium; Essential hypertension; Nitric oxide; Platelets

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE;

ESSENTIAL HYPERTENSION; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; THROMBOCYTE AGGREGATION INHIBITION; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 73649083022     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328330e89a     Document Type: Review

References (145)

1. Palmer RM, Ashton DS, Moneada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333: 664-666.
2. Pollock JS, Forstermann U, Mitchell JA, Warner TD, Schmidt HH, Nakane M, Murad F. Purification and characterization of particulate endotheliumderived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci U S A 1991; 88: 10480-10484. (Pubitemid 21915859)
3. Lamas S, Marsden PA, Li GK, Tempst P, Michel T. Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive enzyme isoform. Proc Natl Acad Sci U S A 1992; 89: 6348-6352.
4. Balllgand JL, Kelly RA, Marsden PA, Smith TW, Michel T. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci U S A 1993; 90: 347-351. (Pubitemid 23010307)
5. Chen LY, Mehta JL. Evidence for the presence of L-arginine-nitric oxide pathway in human red blood cells: relevance in the effects of red blood cells on platelet function. J Cardiovasc Pharmacol 1998; 32: 57-61.
6. Mehta JL, Chen LY, Kone BC, Mehta P, Turner P. Identification of constitutive and Inducible forms of nitric oxide synthase in human platelets. J Lab Clin Med 1995; 125: 370-377.
7. Palmer RM, Rees DD, Ashton DS, Moneada S. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun 1988; 153: 1251-1256.
8. Nishlda K, Harrison DG, Navas JP, Fisher AA, Dockery SP, Uematsu M, et al. Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase. J Clin Invest 1992; 90: 2092-2096.
9. Marsden PA, Schappert KT, Chen HS, Flowers M, Sundell CL, Wilcox JN, et al. Molecular cloning and characterization of human endothelial nitric oxide synthase. FEBS Lett 1992; 307: 287-293.
10. Forstermann U, Pollook JS, Schmidt HH, Heller M, Murad F. Calmodulin-dependent endothelium-derived relaxing factor/nitric oxide synthase activity is present in the particulate and cytosolic fractions of bovine aortic endothelial cells. Proc Natl Acad Sci U S A 1991; 88: 1788-1792. (Pubitemid 21916311)
11. Busse R, Mulsch A. Calcium-dependent nitric oxide synthesis in endothelial cytosol is mediated by calmodulin. FESS Lett 1990; 265: 133-136.
12. Bredt DS, Hwang PM, Glatt CE, Lowensteln C, Reed RR, Snyder SH. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature 1991; 351: 714-718.
13. Lopez-Jaramillo P, Gonzalez MC, Palmer RM, Moneada S. The crucial role of physiological Ca2+ concentrations in the production of endothelial nitric oxide and the control of vascular tone. Br J Pharmacol 1990; 101: 489-493. (Pubitemid 20292911)
14. Butt E, Bernhardt M, Smolenski A, Kotsonls P, Frohlich LG, Sickmann A, et al. Endothelial nitric-oxide synthase (type III) is activated and becomes calcium independent upon phosphorylation by cyclic nucleotide-dependent protein kinases. J Biol Chem 2000; 275: 5179-5187. (Pubitemid 30108921)
15. Fleming I, Fisslthaler B, Dimmeler S, Kemp BE, Busse R. Phosphorylation of Thr(495) regulates Ca(2+)/calmodulln-dependent endothelial nitric oxide synthase activity. Circ Res 2001; 88: E68-75.
16. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399: 601-605. (Pubitemid 29279182)
17. Gallis B, Corthals GL, Goodlett DR, Ueba H, Kim F, Presnell SR, et al. Identification of flow-dependent endothelial nitric-oxide synthase phosphorylation sites by mass spectrometry and regulation of phosphorylation and nitric oxide production by the phosphatidylinosltol 3-kinase inhibitor LY294002. J Biol Chem 1999; 274: 30101-30108. (Pubitemid 129637946)
18. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujlo Y, Walsh K, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999; 399: 597-601. (Pubitemid 29279181)
19. Fisslthaler B, Dimmeler S, Hermann C, Busse R, Fleming I. Phosphorylation and activation of the endothelial nitric oxide synthase by fluid shear stress. Acta Physiol Scand 2000; 168: 81-88. (Pubitemid 30128671)
20. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 1999; 103: 401-406. (Pubitemid 29069990)
21. Lantin-Hermoso RL, Rosenfeld CR, Yuhanna IS, German Z, Chen Z, Shaul PW. Estrogen acutely stimulates nitric oxide synthase activity in fetal pulmonary artery endothelium. Am J Physiol 1997; 273: L119-L126. (Pubitemid 27349331)
22. Haynes MP, Sinha D, Russell KS, Collinge M, Fulton D, Morales-Ruiz M, et al. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res 2000; 87: 677-682. (Pubitemid 30778315)
23. Michell BJ, Harris MB, Chen ZP, Ju H, Venema VJ, Blackstone MA, et al. Identification of regulatory sites of phosphorylation of the bovine endothelial nitric-oxide synthase at serine 617 and serine 635. J Biol Chem 2002; 277: 42344-42351. (Pubitemid 35257555)
24. Boo YC, Hwang J, Sykes M, Michell BJ, Kemp BE, Lum H, Jo H. Shear stress stimulates phosphorylation of eNOS at Ser(635) by a protein kinase A-dependent mechanism. Am J Physiol Heart Circ Physiol 2002; 283: H1819-H1828. (Pubitemid 35217015)
25. Chen ZP, Mltchelhlll Kl, Michell BJ, Stapleton D, Rodriguez-Crespo I, Witters LA, et al. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett 1999; 443: 285-289. (Pubitemid 29080812)
26. Ignarro U, Harbison RG, Wood KS, Kadowitz PJ. Activation of purified soluble guanylate cyclase by endothelium-derived relaxing factor from intrapulmonary artery and vein: stimulation by acetylcholine, bradykinin and arachidonic acid. J Pharmacol Exp Ther 1986; 237: 893-900.
27. Horowitz A, Menice CB, Laporte R, Morgan KG. Mechanisms of smooth muscle contraction. Physiol Rev 1996; 76: 967-1003.
28. Lohmann SM, Vaandrager AB, Smolenski A, Walter U, De Jonge HR. Distinct and specific functions of cGMP-dependent protein kinases. Trends Biochem Sci 1997; 22: 307-312. (Pubitemid 27327088)
29. Rees DD, Palmer RM, Moneada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989; 86: 3375-3378. (Pubitemid 19129614)
30. Vallance P, Collier J, Moneada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone In man. Lancet 1989; 2: 997-1000. (Pubitemid 19257913)
31. Stewart AD, Millasseau SC, Kearney MT, Ritter JM, Chowienczyk PJ. Effects of inhibition of basal nitric oxide synthesis on carotid-femoral pulse wave velocity and augmentation index in humans. Hypertension 2003; 42: 915-918.
32. Haynes WG, Noon JP, Walker BR, Webb DJ. Inhibition of nitric oxide synthesis increases blood pressure In healthy humans. J Hypertens 1993; 11: 1375-1380. (Pubitemid 24008485)
33. Stamler JS, Loh E, Roddy MA, Currie KE, Creager MA. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 1994; 89: 2035-2040. (Pubitemid 24142778)
34. Simon Dl, Stamler JS, Loh E, Loscalzo J, Francis SA, Creager MA. Effect of nitric oxide synthase Inhibition on bleeding time in humans. J Cardiovasc Pharmacol 1995; 26: 339-342.
35. Arnal JF, el Amrani Al, Chatellier G, Menard J, Michel JB. Cardiac weight in hypertension induced by nitric oxide synthase blockade. Hypertension 1993; 22: 380-387.
36. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Flshman MC. Hypertension In mice lacking the gene for endothelial nitric oxide synthase. Nature 1995; 377: 239-242.
37. Huang PL. Disruption of the endothelial nitric oxide synthase gene: effect on vascular response to injury. Am J Cardiol 1998; 82: 57S-59S.
38. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991 ; 88: 4651-4655. (Pubitemid 21914599)
39. Lefer DJ, Jones SP, Girod WG, Baines A, Grisham MB, Cockrell AS, et al. Leukocyte-endothellal cell Interactions in nitric oxide synthase-deficlent mice. Am J Physiol 1999; 276: H1943-H1950. (Pubitemid 29323478)
40. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.
41. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1774-1777. (Pubitemid 19124139)
42. Nakaki T, Nakayama M, Kato R. Inhibition by nitric oxide and nitric oxideproducing vasodilators of DNA synthesis in vascular smooth muscle cells. Eur J Pharmacol 1990; 189: 347-353.
43. Hogg N, Kalyanaraman B, Joseph J, Struck A, Parthasarathy S. Inhibition of low-density lipoprotein oxidation by nitric oxide. Potential role in atherogenesis. FEBS Lett 1993; 334: 170-174. (Pubitemid 23330576)
44. Yates MT, Lambert LE, Whitten JP, McDonald I, Mano M, Ku G, Mao SJ. A protective role for nitric oxide in the oxidative modification of low density lipoproteins by mouse macrophages. FEBS Lett 1992; 309: 135-138.
45. Durante W, Krall MH, Christodoulides N, Peyton KJ, Schafer Al. Nitric oxide induces heme oxygenase-1 gene expression and carbon monoxide production in vascular smooth muscle cells. Circ Res 1997; 80: 557-564. (Pubitemid 27137293)
46. Radomskl MD, Palmer MJR, Moneada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 1987; 148: 1482-1489. (Pubitemid 18074679)
47. Radomski MW, Palmer RM, Moneada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987; 2: 1057-1058. (Pubitemid 17154788)
48. Radomskl MD, Palmer MJR, Moneada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 1987; 92: 181-187. (Pubitemid 17134934)
49. Radomski MW, Palmer RM, Moneada S. The antiaggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987; 92: 639-646.
50. Moro MA, Russel RJ, Cellek S, Lizasoain I, Su Y, Darley-Usmar VM, et al. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci U S A 1996; 93: 1480-1485. (Pubitemid 26075149)
51. Benjamin N, Dutton JA, Ritter JM. Human vascular smooth muscle cells inhibit platelet aggregation when incubated with glyceryl trinitrate: evidence for generation of nitric oxide. Sr J Pharmacol 1991; 102:847-850.
52. Kuhlencordt PJ, Gyurko R, Han F, Scherrer-Crosbie M, Aretz TH, Hajjar R, et al. Accelerated atherosclerosis, aortic aneurysm formation and ischemic heart disease In apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation 2001; 104: 448-454. (Pubitemid 32678276)
53. Chen J, Kuhlencordt PJ, Astern J, Gyurko R, Huang PL. Hypertension does not account for the accelerated atherosclerosis and development of aneurysms in male apolipoprotein e/endothelial nitric oxide synthase double knockout mice. Circulation 2001; 104: 2391-2394. (Pubitemid 33108369)
54. Kuhlencordt PJ, Rosel E, Gerszten RE, Morales-Ruiz M, Dombkowskl D, Atkinson WJ, ef al. Role of endothelial nitric oxide synthase in endothelial activation: insights from eNOS knockout endothelial cells. Am J Physiol Cell Physiol 2004; 286: C1195-C1202. (Pubitemid 38506935)
55. Sase K, Michel T. Expression of constitutive endothelial nitric oxide synthase in human blood platelets. Life Sci 1995; 57: 2049-2055.
56. Radomskl MD, Palmer MJR, Moneada S. Characterization of the L-arginine:nitric oxide pathway in human platelets. Br J Pharmacol 1990; 101: 325-328. (Pubitemid 20292885)
57. Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keany JF, Michelson AD. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 1997; 100: 350-356. (Pubitemid 27349081)
58. Wlnther K, Klysner R, Geisler A, Andersen PH. Characterization of human platelet beta-adrenoceptors. Thromb Res 1985; 40: 757-767.
59. Kerry R, Scrutton MC. Platelet beta-adrenoceptors. Br J Pharmacol 1983; 79: 681-691.
60. Queen LR, Xu B, Horlnouohi K, Fisher I, Ferro A. Beta(2)-adrenoceptors activate nitric oxide synthase in human platelets. Circ Res 2000; 87: 39-44. (Pubitemid 30456933)
61. Trovati M, Massucco P, Mattiello L, Piretto V, Cavalot F, Mularoni E, Anfossi G. The insulin-induced increase of guanosine-3',5'-cyclic monophosphate in human platelets is mediated by nitric oxide. Diabetes 1996; 45: 768-770. (Pubitemid 26166773)
62. Fleming I, Schulz C, Fichtischerer B, Kemp BE, Fisslthaler B, Busse R. AMP-actlvated protein kinase (AMPK) regulates the nsulin-induced activation of the nitric oxide synthase in human platelets. Thromb Haemost 2003; 90: 863-871. (Pubitemid 37427856)
63. Gkaliagkousi E, Ritter J, Ferro A. Platelet-derived nitric oxide signalling and regulation. Circ Res 2007; 101: 654-662. (Pubitemid 47494096)
64. Goubareva I, Gkaliagkousi E, Shah A, Queen L, Ritter J, Ferro A. Age decreases nitric oxide synthesis and responsiveness in human platelets and Increases formation of monocyte-platelet aggregates. Cardiovasc Res 2007; 75: 793-802. (Pubitemid 47238740)
65. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-844. (Pubitemid 30943820)
66. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endotheliumdependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22-27. (Pubitemid 20209468)
67. Linder L, Klowski W, Buhler FR, Luscher TF. Indirect evidence for release of endothelium-derived relaxing factor In human forearm circulation in vivo. Blunted response in essential hypertension. Circulation 1990; 81: 1762-1767. (Pubitemid 20183824)
68. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endotheliumderived nitric oxide In the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993; 87: 1468-1474. (Pubitemid 23133089)
69. Taddei S, Vlrdis A, Mattel P, Ghladoni L, Gennarl A, Fasolo CB, et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 1995; 91: 1981-1987.
70. Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, et al. Asymmetric dimethylarginine, L-arginlne and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005; 46: 518-523. (Pubitemid 41040296)
71. Calver A, Collier J, Moneada S, Vallance P. Effect of local intra-arterial NG-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens 1992; 10: 1025-1031.
72. Taddei S, Virdis A, Ghladoni L, Magagna A, Salvetti A. Cyclooxygenase Inhibition restores nitric oxide activity In essential hypertension. Hypertension 1997; 29: 274-279. (Pubitemid 27074055)
73. Perticone F, Ceravolo R, Maio R, Ventura G, lacopino S, Cuda G, et al. Calcium antagonist isradipine improves abnormal endotheliumdependent vasodilation in never treated hypertensive patients. Cardiovasc Res 1999; 41: 299-306. (Pubitemid 29016070)
74. Calver A, Collier J, Vallance P. Forearm blood flow responses to a nitric oxide synthase inhibitor in patients with treated essential hypertension. Cardiovasc Res 1994; 28: 1720-1725. (Pubitemid 24344148)
75. Rossi GP, Taddei S, Virdis A, Cavallin M, Ghiadoni L, Favilla S, et al. The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients. JAm Coll Cardiol 2003; 41: 938-945. (Pubitemid 36315533)
76. Donald AE, Charaklda M, Cole TJ, Frlberg P, Chowienczyk PJ, Millasseau SC, et al. Noninvasive assessment of endothelial function: which technique? J Am Coll Cardiol 2006; 48: 1846-1850. (Pubitemid 44648611)
77. Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, Deanfield JE. Cigarette smoking is associated with dose-related and potentially reversible impairment of endotheliumdependent dilation in healthy young adults. Circulation 1993; 88: 2149-2155. (Pubitemid 23326094)
78. Celermajer DS, Adams MR, Clarkson P, Robinson J, McCredie R, Donald A, Deanfield JE. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. W Engl J Med 1996; 334: 150-154. (Pubitemid 26017952)
79. Clarkson P, Celermajer DS, Donald AE, Sampson M, Sorensen KE, Adams M, et al. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J Am Coll Cardiol 1996; 28: 573-579. (Pubitemid 126745496)
80. liyama K, Nagano M, Yo Y, Nagano N, Kamide K, Hlgaki J, et al. Impaired endothelial function with essential hypertension assessed by ultrasonography. Am Heart J 1996; 132: 779-782.
81. Muiesan ML, Salvetti M, Monteduro C, Corbellini C, Guelfi D, Rizzoni D, et al. Flow-mediated dilatation of the brachial artery and left ventricular geometry in hypertensive patients. J Hypertens 2001 ; 19: 641-647. (Pubitemid 32280958)
82. Muiesan ML, Salvetti M, Monteduro C, Rizzoni D, Zulli R, Corbellini C, et al. Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension. Hypertension 1999; 33: 575-580. (Pubitemid 29065723)
83. Koh KK. Comparison of effects of losarían, irbesartan, and candesartan on FMD. Am J Cardiol 2004; 93:1432-1435.
84. Ghiadoni L1 Magagna A, Versari D, Kardasz I, Huang Y, Taddei S, Salvetti A. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41: 1281-1286. (Pubitemid 36706078)
85. Ghladoni L, Versari D, Magagna A, Kardasz I, Plantinga Y, Glannarelli C, et al. Ramipril dose-dependently increases nitric oxide availability In the radial artery of essential hypertension patients. J Hypertens 2007; 25: 361-366. (Pubitemid 46071933)
86. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation In the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994; 24: 1468-1474. (Pubitemid 24344241)
87. lmaoka Y, Osanai T, Kamada T, Mio Y, Satoh K, Okumura K. Nitric oxidedependent vasodilator mechanism is not impaired by hypertension but is diminished with aging in the rat aorta. J Cardiovasc Pharmacol 1999; 33: 756-761.
88. Thuraisingham RC, Raine AE. Maintenance of normal agonist-induced endothelium-dependent relaxation in uraemic and hypertensive resistance vessels. Nephrol Dial Transplant 1999; 14: 70-75.
89. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-medlated hypertension In the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-1923. (Pubitemid 26129879)
90. Angus JA, Dyke AC, Jennings GL, Korner Pl, Sudhir K, Ward JE, Wright CE. Release of endothelium-derived relaxing factor from resistance arteries in hypertension. Kidney lnt Suppl 1992; 37: S73-S78.
91. Cockcroft JR, Chowlenczyk PJ, Benjamin N, Ritter JM. Preserved endothelium-dependent vasodilatation in patients with essential hypertension. W Engl J Med 1994; 330: 1036-1040. (Pubitemid 24106560)
92. Kneale BJ, Chowienczyk PJ, Brett SE1 Cockcroft JR, Ritter JM. Forearm vasoconstriction in response to noradrenaline and NG-monomethyl-L-arginine in essential hypertension. Clin Sci (Lond) 1999; 97: 277-282.
93. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 2005; 111: 363-368.
94. Duff F, Greenfield AD, Shepherd JT, Thompson ID. A quantitative study of the response to acetylcholine and histamine of the blood vessels of the human hand and forearm. J Physiol 1953; 120: 160-170.
95. Chowienczyk PJ, Cockcroft JR, Ritter JM. Blood flow responses to intraarterial acetylcholine in man: effects of basal flow and conduit vessel length. Clin Sci (Lond) 1994; 87: 45-51.
96. Chowienczyk PJ, Cockcroft JR, Ritter JM. Differential Inhibition by NG-monomethyl-L-arginine of vasodilator effects of acetylcholine and methacholine in human forearm vasculature. Br J Pharmacol 1993; 110: 736-738.
97. Gold ME, Wood KS, Byrns RE, Fukuto J, lgnarro LJ. NG-methyl-L-arginine causes endothelium-dependent contraction and inhibition of cyclic GMP formation in artery and vein. Proc Natl Acad Sci U S A 1990; 87: 4430-4434. (Pubitemid 20204114)
98. Rees DD, Palmer RM, Hodson HF, Moneada S. A specific inhibitor of nitric oxide formation from L-arginlne attenuates endothelium-dependent relaxation. Br J Pharmacol 1989; 96: 418-424.
99. Bogle RG, Moneada S, Pearson JD, Mann GE. Identification of Inhibitors of nitric oxide synthase that do not interact with the endothelial cell L-arglnine transporter. Br J Pharmacol 1992; 105:768-770.
100. Moss MB, Brunini TM, Soares De Moura R, Novaes Malagris LE, Roberts NB, Ellory JC, et al. Diminished L-arginine bioavailability in hypertension. Clin Sci (Lond) 2004; 107: 391-397.
101. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection E and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
102. Chowienczyk PJ, Watts GF, Cockcroft JR, Ritter JM. Impaired endothelium-dependent vasodilation of forearm resistance vessels In hypercholesterolemia. Lancet 1992; 340: 1430-1432.
103. Steinberg HO, Chaker H, Learning R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 2601-2610. (Pubitemid 26187348)
104. Kiowski W, Linder L, Stoschitzky K, Pfisterer M, Burckhardt D, Burkart F, Buhler FR. Diminished vascular response to inhibition of endothelium-derived nitric oxide and enhanced vasoconstriction to exogenously administered endothelin-1 in clinically healthy smokers. Circulation 1994; 90: 27-34. (Pubitemid 24203659)
105. Petrie JR, Ueda S, Webb DJ, Elliott HL, Connell JM. Endothelial nitric oxide production and insulin sensitivity. A physiological link with Implications for pathogenesis of cardiovascular disease. Circulation 1996; 93: 1331-1333. (Pubitemid 26099342)
106. Butler R, Morris AD, Struthers AD. Cigarette smoking In men and vascular responsiveness. Br J Clin Pharmacol 2001; 52: 145-149. (Pubitemid 32863071)
107. Wlerzbicki AS, Chowienczyk PJ, Cockcroft JR, Brett SE, Watts GF, Jenkins BS, Ritter JM. Cardiovascular risk factors and endothelial dysfunction. Clin Sci (Lond) 2004; 107: 609-615. (Pubitemid 39627208)
108. Chan NN, Colhoun HM, Vallance P. Cardiovascular risk factors as determinants of endothelium-dependent and endothellum-independent vascular reactivity in the general population. J Am Coll Cardiol 2001; 38: 1814-1820. (Pubitemid 33116549)
109. Taddei S, Virdis A, Mattei P, Ghiadoni L, Sudano I, Salvetti A. Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation 1996; 94: 1298-1303. (Pubitemid 26307256)
110. Millgard J, Lind L. Acute hypertension impairs endothelium-dependent vasodilation. Clin Sci (Lond) 1998; 94: 601-607. (Pubitemid 28269059)
111. Paniagua OA, Bryant MB, Panza JA. Translent hypertension directly Impairs endothelium-dependent vasodilation of the human microvasculature. Hypertension 2000; 36: 941-944.
112. Lyons D, Webster J, Benjamin N. The effect of antihypertensive therapy on responsiveness to local intra-arterial NG-monomethyl-L-arginine in patients with essential hypertension. J Hypertens 1994; 12: 1047-1052. (Pubitemid 24294816)
113. Taddei S, Virdis A, Ghiadoni L, Uleri S, Magagna A, Salvetti A. Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients. Hypertension 1997; 30: 1606-1612. (Pubitemid 27528112)
114. Higashi Y, Sasaki S, Nakagawa K, Ueda T, Yoshlmizu A, Kurlsu S, et al. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study. J Am Coll Cardiol 2000; 35: 284-291. (Pubitemid 30125515)
115. Prasad A, Tupas-Habib T, Schenke WH, Mincemoyer R, Panza JA, Waclawin MA, et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 2000; 101: 2349-2354. (Pubitemid 30329123)
116. Creager MA, Roddy MA. Effect of Captopril and enalaprll on endothelial function in hypertensive patients. Hypertension 1994; 24: 499-505. (Pubitemid 24296474)
117. Kiowski W, Linder L, Nuesch R, Martina B. Effects of Cilazapril on vascular structure and function in essential hypertension. Hypertension 1996; 27: 371-376. (Pubitemid 26083054)
118. Taddei S, Virdis A, Ghladoni L, Magagna A, Pasini AF, Garbin U, et al. Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients. J Hypertens 2001; 19: 1379-1386. (Pubitemid 32730454)
119. Taddei S, Virdis A, Ghiadoni L, Mattel P, Salvetti A. Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation In essential hypertensive patients. J Hypertens 1998; 16: 447-456. (Pubitemid 28195854)
120. Dawes M, Brett SE, Chowienczyk PJ, Mant TG, Ritter JM. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol 1999; 48: 460-463. (Pubitemid 29417735)
121. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 2001; 104: 511-514. (Pubitemid 32738117)
122. Ritter JM. Nebivolol: endothelium-mediated vasodilating effect. J Cardiovasc Pharmacol 2001; 38 (Suppl 3): S13-S16.
123. Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CP, Dupont AG, Van Nueten L, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274: 1067-1071.
124. Mason RP. Mechanisms of plaque stabilization for the dihydropyrldine calcium channel blocker amlodipine: review of the evidence. Atherosclerosis 2002; 166: 191-199.
125. Hishikawa K, Luscher TF. Felodipine inhibits free-radical production by cytokines and glucose in human smooth muscle cells. Hypertension 1998; 32: 1011-1015. (Pubitemid 29001428)
126. Mak IT, Boehme P, Wegllcki WB. Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Correlation of protection with preservation of glutathione levels. Circ Res 1992; 70: 1099-1103.
127. Zhou MS, Jaimes EA, Raij L. Inhibition of oxidative stress and improvement of endothelial function by amlodipine In angiotensin ll-lnfused rats. Am J Hypertens 2004; 17: 167-171. (Pubitemid 38125135)
128. Shesely EG, Maeda N, Kim HS, Desai KM, Krege JH, Laubach VE, et al. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1996; 93: 13176-13181. (Pubitemid 26382789)
129. Hyndman ME, Parsons HG, Verma S, Bridge PJ, Edworthy S, Jones C, et al. The T-786→C mutation In endothelial nitric oxide synthase is associated with hypertension. Hypertension 2002; 39: 919-922. (Pubitemid 34437550)
130. Kato N, Sugiyama T, Morita H, Nabika T, Kurihara H, Yamori Y, Yazaki Y. Lack of evidence for association between the endothelial nitric oxide synthase gene and hypertension. Hypertension 1999; 33: 933-936. (Pubitemid 29186387)
131. Bonnardeaux A, Nadaud S, Charm A, Jeunemaitre X, Corvol P, Soubrier F. Lack of evidence for linkage of the endothelial cell nitric oxide synthase gene to essential hypertension. Circulation 1995; 91: 96-102.
132. Benjamin EJ, Larson MG, Keyes MJ, Mitchell GF, Vasan RS, Keaney JF Jr, et al. Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study. Circulation 2004; 109: 613-619. (Pubitemid 38198868)
133. Cadwgan TM, Benjamin N. Evidence for altered platelet nitric oxide synthesis in essential hypertension. J Hypertens 1993; 11: 417-420. (Pubitemid 23139784)
134. Bruninl T, Moss M, Siqueira M, Meirelles L, Rozentul A, Mann G, Mendes-Ribeiro A. Inhibition of l-arginine transport in platelets by asymmetric dimethylarginine and N-monomethyl-l-arginine: effects of arterial hypertension. Clin Exp Pharmacol Physiol 2004; 31: 738-740. (Pubitemid 39540326)
135. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boeger RH, Bode-Boeger SM, et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33: 652-658. (Pubitemid 29164831)
136. Goonasekera CD, Rees DD, Woolard P, Frend A, Shah V, Dillon MJ. Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens 1997; 15: 901-909. (Pubitemid 27344855)
137. Camilletti A, Moretti N, Giacchetti G, FaIoIa E, Martarelli D, Mantera F, Mazzanti L. Decreased nitric oxide levels and increased calcium content in platelets of hypertensive patients. Am J Hypertens 2001; 14: 382-386. (Pubitemid 32337144)
138. Gkaliagkousi E, Queen LR, Ritter J, Ferra A. Nitric oxide synthase activation is impaired in platelets from patients with essential hypertension. Circ Suppl 2005; 112: 11-73; 439 (abst).
139. lkeda H, Takajo Y, Murohara T, Ichiki K, Adachi H, Haramaki N, et al. Platelet-derived nitric oxide and coronary risk factors. Hypertension 2000; 35: 904-907.
140. Gkaliagkousi E, Corrigal V, Zamboulis C, Ritter J, Ferro A. Circulating monocyte-platelet aggregates increase with increasing levels of blood pressure. Eur Heart J 2006; 27 (Abstract Suppl): 754.
141. Koh KK, Han SH, Chung WJ, Ahn JY, Jin DK, Kim HS, et al. Comparison of effects of losartan, irbesartan and candesartan on flow-mediated brachial artery dilatation and on inflammatory and thrombolytic markers In patients with systemic hypertension. Am J Cardiol 2004; 93: 1432-1435.
142. Pasinl AF, Garbin U, Stranleri C, Boccioletti V, Mozzini C, Manfro S, et al. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am J Hypertens 2008; 21: 1261-11257
143. Benndorf RA, Appel D, Maas R, Schwedhelm E, Wenzel UO, Böger RH. Telmisartan improves endothelial function in patients with essential hypertension. J Cardiovasc Pharmacol 2007; 50: 367-371.
144. Buus NH, Jergensen CG, Mulvany MJ, Serensen KE. Large and small artery endothelial function in patients with essential hypertension: effect of ACE inhibition and beta-blockade. Blood Press 2007; 16: 106-113.
145. Plantinga Y, Ghiadoni L, Magagna A, Giannarelli C, Franzoni F, Taddei S,